Ebvallo is a clinical-stage drug being developed for the treatment of Epstein–Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV-PTLD) is a life-threatening lymphoid disorder that occurs in patients who have undergone solid-organ transplantation (SOT) or allogeneic hematopoietic stem-cell transplantation (HSCT) and are receiving immunosuppressive therapy. Immunosuppression weakens the body’s normal T-cell defences against EBV. When these defences are lowered, EBV can spread more easily and infect B cells, causing them to grow and multiply uncontrollably. EBV-PTLD can progress into aggressive lymphoma, infiltrate multiple organs, cause multi-organ dysfunction, and is frequently fatal if untreated. The overall incidence of PTLD is approximately 1–20% after SOT and 0.8–4.5% after HSCT (1), and about two-thirds of PTLD cases are EBV-positive (2).. It is being developed by Atara Biotherapeutics, Inc.. The FDA Prescription Drug User Fee Act (PDUFA) date is January 9, 2026. Premium analysis including detailed clinical trial status, revenue predictions, and comprehensive company insights are available for members.